Zealand Pharma A/S American Depositary Shares
ZEAL
ZEAL was delisted on the 29th of September, 2022.
13 hedge funds and large institutions have $71.7M invested in Zealand Pharma A/S American Depositary Shares in 2019 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
15% more capital invested
Capital invested by funds: $62.2M → $71.7M (+$9.45M)
0% more funds holding
Funds holding: 13 → 13 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$270K |
| 2 |
Renaissance Technologies
New York
|
+$240K |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$226K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$173K |
| 5 |
Morgan Stanley
New York
|
+$40.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.79M |
| 2 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
-$476K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$31.8K |
| 4 |
JP Morgan Chase
New York
|
-$12K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$655 |
ZEAL Hedge Fund Activity: Q3 2019 in Review
13 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Zealand Pharma A/S American Depositary Shares (ZEAL) for Q3 2019, worth a combined $71.7M — up 15% from $62.2M a quarter earlier.
Fund positioning in ZEAL was balanced in Q3 2019: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 3 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $270K. The largest seller was Wellington Management Group, cutting an estimated $1.79M.
- 13 institutional investors held Zealand Pharma A/S American Depositary Shares (ZEAL) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $71.7M of Zealand Pharma A/S American Depositary Shares stock for Q3 2019, up 15% quarter-over-quarter.
- 2 funds opened new Zealand Pharma A/S American Depositary Shares positions in Q3 2019 and 2 closed out, a net change of 0 holders.
- The largest Zealand Pharma A/S American Depositary Shares buyer in Q3 2019 was Jane Street, an estimated $270K added.
- The largest Zealand Pharma A/S American Depositary Shares seller in Q3 2019 was Wellington Management Group, an estimated $1.79M sold.
Based on aggregated 13F filings for Q3 2019.